🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchOrforglipron ATTAIN-4 — my results so far Page 3

Orforglipron ATTAIN-4 — my results so far

roxy_nash Sat, Jul 12, 2025 at 6:46 AM 43 replies 2,076 viewsPage 3 of 9
Dr.MetabolicMD
VIP Member
2,345
16,789
Jan 2024
Rochester, MN
Jul 14, 2025 at 8:57 PM#11
rachel_ABQ said:
It helps to ask what evidence would change your mind before you look at any.

That holds where the measurement is reliable. Where it is noisy — and a lot of what gets tracked here is noisy — the same reasoning produces confident nonsense.

Happy to go further on any of that.

9 7SleepDoc_PDX, RegAffairsDC, BiostatsBrad and 6 others
Reply Quote Save Share Report
DadBodDave
Member
187
923
Nov 2024
Ohio
Jul 16, 2025 at 11:43 PM#12
Dr.PathRoch said:
Orforglipron is a small molecule rather than a peptide, which is the whole point: no SNAC absorption enhancer, no fasting window, no cold chain, and…

Thank you — that is the clearest version of this I have read, and I have read a lot of them. Sending this to two other people who asked me the same thing last week.

10 8JenMemphis, pat_auckland, Dr.GastroMayo and 7 others
Reply Quote Save Share Report
kevin_tulsa
Member
489
2,123
Jun 2024
Tulsa, OK
Jul 19, 2025 at 2:30 AM#13
rachel_ABQ said:
It helps to ask what evidence would change your mind before you look at any.

Careful with the causal language. Two things moving together in a period when five things changed is not a mechanism, and stating it as one makes the thread less useful to somebody reading it later.

Last edited: Jul 19, 2025 at 4:30 AM
11 9greg_boulder, quinn_sf, NurseLeah_Nash and 8 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
josh_phd_bmore
Member
389
1,678
Jul 2024
Baltimore, MD
Jul 21, 2025 at 5:18 AM#14

One concrete data point for the thread. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.

12 10KarenAZ_mom, zoe_NC, Dr.ObesityLA and 9 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Jul 23, 2025 at 8:07 AM#15

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Tagging this one for the weekly digest.

13 11PurityPaulOR, MaxMetOK, MounjBrad and 10 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register